SecBot SecBot
PRESS-RELEASE ·Filed Jun 1, 2026

IMTX

https://immatics.com/
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

Positive efficacy and durability data reinforce anzu-cel's potential in melanoma; investors should watch for SUPRAME Phase 3 enrollment progress and any competitive developments. The 1H 2027 BLA submission timeline provides a medium-term catalyst.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.14
T+0 close · Jun 1, 2026 · via day close
Latest settled
−17.06%
T+60 · $9.24
Vs SPY
−18.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $11.14entry
  2. T+1 · 6mo ago −9.87%α −10.02% · $10.04
  3. T+5 · 5mo ago −12.12%α −9.37% · $9.79
  4. T+20 · 5mo ago −9.07%α −7.77% · $10.13
  5. T+60 · 3mo ago −17.06%α −18.29% · $9.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, showing 56% confirmed ORR, 14.6-month median DOR, 6.1-month median PFS, and 16.2-month median OS with manageable safety. The Phase 3 SUPRAME trial remains on track with BLA submission expected in 1H 2027.

Key Facts

  • 56% confirmed objective response rate (cORR) in heavily pretreated metastatic melanoma (N=33)
  • Median duration of response (mDOR) of 14.6 months; median PFS 6.1 months; median OS 16.2 months
  • Phase 3 SUPRAME trial advancing; BLA submission targeted for 1H 2027
  • Predictable and manageable safety profile with mostly Grade 1-2 CRS and infrequent ICANS
  • Anzu-cel demonstrated systemic anti-tumor activity across multiple metastatic sites including liver, lung, and brain

Financial Impact

Positive clinical data supports the potential of anzu-cel as a first-in-class PRAME-directed cell therapy, though no financial figures provided.

pipeline valuemarket cap

Risk Factors

  • Data is from Phase 1b; Phase 3 may not replicate results
  • Competitive landscape includes approved checkpoint inhibitors and other cell therapies
  • Regulatory approval and commercial launch are uncertain and costly

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304266

Track record

23 reports on IMTX

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
  3. Nov 10, 20266d ago 6-K Neutral 5/10 No price data
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
  5. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  6. Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  7. Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
  8. Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
  9. Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
  10. Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026